NasdaqGS:LEGNBiotechs
Legend Biotech (LEGN) Valuation Check As Board Changes And CARVYKTI Sales Update Draw Attention
Legend Biotech (LEGN) has seen a flurry of boardroom changes and fresh sales data that could interest investors, highlighted by the appointment of Gareth Kung as a Class II director and the new Audit Committee chair.
See our latest analysis for Legend Biotech.
These boardroom changes and the recent CARVYKTI sales update come after a steep 90 day share price return of 46.23% decline and a 1 year total shareholder return of 51.67% loss, suggesting momentum has been weak despite operational...